Eledon pharmaceuticals reports third quarter 2023 operating and financial results

Reported updated data from ongoing phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function first participant dosed in phase 2 bestow trial evaluating tegoprubart for the prevention of rejection in kidney transplantation irvine, calif., nov. 09, 2023 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its third quarter operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking